Cargando…
Conditionality of COVID-19 vaccine acceptance in European countries
The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more conta...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806150/ https://www.ncbi.nlm.nih.gov/pubmed/35125225 http://dx.doi.org/10.1016/j.vaccine.2022.01.054 |
_version_ | 1784643380335083520 |
---|---|
author | Heyerdahl, Leonardo W. Vray, Muriel Lana, Benedetta Tvardik, Nastassia Gobat, Nina Wanat, Marta Tonkin-Crine, Sarah Anthierens, Sibyl Goossens, Herman Giles-Vernick, Tamara |
author_facet | Heyerdahl, Leonardo W. Vray, Muriel Lana, Benedetta Tvardik, Nastassia Gobat, Nina Wanat, Marta Tonkin-Crine, Sarah Anthierens, Sibyl Goossens, Herman Giles-Vernick, Tamara |
author_sort | Heyerdahl, Leonardo W. |
collection | PubMed |
description | The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more contagious variants. This cross-sectional survey was conducted online just before the European vaccine rollout in December 2020 among 7000 respondents (aged 18–65) in Belgium, France, Germany, Italy, Spain, Sweden, and Ukraine. The survey included open text boxes for fuller explanation of responses. Overall, 56.9% of respondents would accept a COVID-19 vaccine, 19.0% would not, and 24.1% did not know or preferred not to say. By country, between 44% (France) and 66% (Italy) of respondents would accept a COVID-19 vaccine. Respondents expressed conditionality in open responses, voicing concerns about vaccine safety and mistrust of authorities. We highlight lessons learned about the dynamism of vaccine conditionality and persistence of safety concerns. |
format | Online Article Text |
id | pubmed-8806150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88061502022-02-02 Conditionality of COVID-19 vaccine acceptance in European countries Heyerdahl, Leonardo W. Vray, Muriel Lana, Benedetta Tvardik, Nastassia Gobat, Nina Wanat, Marta Tonkin-Crine, Sarah Anthierens, Sibyl Goossens, Herman Giles-Vernick, Tamara Vaccine Short Communication The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more contagious variants. This cross-sectional survey was conducted online just before the European vaccine rollout in December 2020 among 7000 respondents (aged 18–65) in Belgium, France, Germany, Italy, Spain, Sweden, and Ukraine. The survey included open text boxes for fuller explanation of responses. Overall, 56.9% of respondents would accept a COVID-19 vaccine, 19.0% would not, and 24.1% did not know or preferred not to say. By country, between 44% (France) and 66% (Italy) of respondents would accept a COVID-19 vaccine. Respondents expressed conditionality in open responses, voicing concerns about vaccine safety and mistrust of authorities. We highlight lessons learned about the dynamism of vaccine conditionality and persistence of safety concerns. The Author(s). Published by Elsevier Ltd. 2022-02-23 2022-02-01 /pmc/articles/PMC8806150/ /pubmed/35125225 http://dx.doi.org/10.1016/j.vaccine.2022.01.054 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Heyerdahl, Leonardo W. Vray, Muriel Lana, Benedetta Tvardik, Nastassia Gobat, Nina Wanat, Marta Tonkin-Crine, Sarah Anthierens, Sibyl Goossens, Herman Giles-Vernick, Tamara Conditionality of COVID-19 vaccine acceptance in European countries |
title | Conditionality of COVID-19 vaccine acceptance in European countries |
title_full | Conditionality of COVID-19 vaccine acceptance in European countries |
title_fullStr | Conditionality of COVID-19 vaccine acceptance in European countries |
title_full_unstemmed | Conditionality of COVID-19 vaccine acceptance in European countries |
title_short | Conditionality of COVID-19 vaccine acceptance in European countries |
title_sort | conditionality of covid-19 vaccine acceptance in european countries |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806150/ https://www.ncbi.nlm.nih.gov/pubmed/35125225 http://dx.doi.org/10.1016/j.vaccine.2022.01.054 |
work_keys_str_mv | AT heyerdahlleonardow conditionalityofcovid19vaccineacceptanceineuropeancountries AT vraymuriel conditionalityofcovid19vaccineacceptanceineuropeancountries AT lanabenedetta conditionalityofcovid19vaccineacceptanceineuropeancountries AT tvardiknastassia conditionalityofcovid19vaccineacceptanceineuropeancountries AT gobatnina conditionalityofcovid19vaccineacceptanceineuropeancountries AT wanatmarta conditionalityofcovid19vaccineacceptanceineuropeancountries AT tonkincrinesarah conditionalityofcovid19vaccineacceptanceineuropeancountries AT anthierenssibyl conditionalityofcovid19vaccineacceptanceineuropeancountries AT goossensherman conditionalityofcovid19vaccineacceptanceineuropeancountries AT gilesvernicktamara conditionalityofcovid19vaccineacceptanceineuropeancountries |